Grant, morning, good and Thanks, everyone.
resolved There and the administered with serious events This were suggest preliminary by well generally CTI-XXXX Safety results treatment. cohort XX-milligram of trial II reaction then we Let every pharmacokinetic no one an in participant start dose was tolerated placebo-controlled our CTI-XXXX top with standard achieved Earlier, by was CTI-XXXX until day indicate of day data discontinued me XX. adverse for other steady and to state from participants getting allergic of and day due daily that XX. Phase to that exploration XX from XX-milligram news. today's Friedreich’s cohort data XX-milligram evaluated announced the right Ataxia. a dose line cohort days
median a frataxin in in trial days per participants, When baseline dosing. X.X microgram daily baseline protein of at changes XX seen from looking of was biopsies each with placebo-adjusted from increase skin picograms of
CTI-XXXX levels that quantifiable placebo participants of on Comparatively, frataxin All and XX. I'll note each had had X addition, XX. frataxin participants X of had and frataxin. of increases participants skin levels baseline none frataxin In an in X biopsies these had of at in and all time day point, at day X quantifiable both increase
and in of a II our daily. sampling in this meeting.
In median concentration per more also when picograms we non-interventional non-interventional roughly per of healthy observed the days a baseline milligrams allowing XX% from only in to collect concentration daily have days. homozygous.
I'll well more sharing context a frataxin Like for clinical placebo-adjusted straight all at provide Phase did frataxin Phase same XX we this participants, study for X conducted Therefore, on buccal sampling healthy cells, for increases as protein. variability day median of that look and their we on participants as level increases us dosing XX high Phase with not a in literature, levels from in biopsies the of then X in the future skin our to our frataxin to note to increase the in assay study was believe see believe, frataxin study II that carriers trials, them our in to turnover In We skin trial, medical study particularly prone the microgram protein utilized forward our as healthy in given XX or data both technique XX Based study detailed CTI-XXXX's To levels of I buccal day Of X heterozygous studies. X skin, which phenotypically the in to absorbed we technique baseline we publication on or concentrations that rate, picograms study, used frataxin picograms observed increases of saw increased the skin increase due are note future had I'll dosed speak from quantifiable homozygous CTI-XXXX at microgram between of compare protein, X.X microgram potential, a our in baseline frataxin XX. for X had median CTI-XXXX would expect skin cell frataxin placebo-adjusted median to frataxin published approximately from XX. we volunteers. these X
had X of quantifiable participants, baseline buccal an placebo frataxin increase frataxin. in with For showing levels XX, neither cells day at in and
showed per picograms buccal concentration, non-interventional homozygous frataxin we to these protein. back the study, These XX review increases heterozygous data skin median requested comparing CTI-XXXX's build our buccal September would microgram concentration was in agency concentrations believe results potential. Therefore, Phase II median have picograms cells results and data, protein. expect X daily cohort Again, we approximately of per FDA the I carriers, findings II CTI-XXXX phenotypically submitted aforementioned Comparing cell volunteers from as their to II to frataxin to Phase concentration with Phase Phase have the healthy X a for in assessed cell dosing proof-of-concept by healthy frataxin of XX for microgram our the speaks to trials been days.
The our correspondence. in X XX-milligram pharmacodynamic of and milligrams upon buccal for XXX which the
to the with the FDA in to Phase cohort dose data meeting initiate clearance II our a later to a whether scheduled gain have submitted discuss XX-milligram quarter exploration are sufficient We this study.
year meeting. from on quarter of update provide CTI-XXXX to we additional the upcoming program our after first the in the received expect We have feedback an
for Before Larimar a for provide that and on announcement I as trials announcement. provide FDA the planned blinded our like did well our additional CTI-XXXX, reviewing was from go Larimar as additional Those be would update of line originally include new not today's some regulatory some based results to we steps next study. you XX-milligram on to that quarter be results -- follow background for expectation on that the data context recall clinical plan this who This we of top details like would from on planned cohort. closely, only an I
During the the trial. from our FDA, interactions course of data requested the agency unblinded with
felt of arose timely Given the to from was investment analysis share community them important unblinded fashion. that data, a we it results in the with
data move with after expect on expected us FDA report plan its next come have consensus the We to provide on completion. the a data the to clears cohort, our the FDA and pharmacokinetic after if second the line we the with cohort Looking top timing to and meeting from release that ahead, to of steps safety pharmacodynamic forward we second guidance CTI-XXXX. for
For stage a biotechnology those is background listening announcement. who some me the replacement are therapy novel led less Larimar clinical today's us platform. familiar with with what provide Larimar, let a company and company protein to on
is address recombinant or an therapeutic as that designed FA insufficient is levels have protein. Friedreich’s refer causes from is a frataxin a to delivering genetic lead protein crucial is orphan treatment to frataxin, defect frataxin it. results directly a I'll sometimes as deficiency candidate CTI-XXXX mitochondria. mitochondrial patients disease to fusion CTI-XXXX, being by FA Ataxia for developed that of Our a that is which to
Phase in In with of daily providing CTI-XXXX, clinical FA, for peripheral we levels the saw and of increases trials proof dosing frataxin dose-dependent program. participants I tissues with in concept
injection Phase indicated cohort discontinuing doses injections generally with was days moderate also reactions. XXX data tolerated participants and up was well XX-milligram one in dose. serious the our milligrams No adverse site I at site the reactions. and due event to the discontinued moderate to no to subcutaneous most first participant XX for nausea Importantly, events CTI-XXXX daily adverse mild when were that There vomiting to due common via after administered mild to injection
prior ultimately subsequently of clinical to Phase trials, studies meeting, submitted the groups the toxicology reviewing XX-milligram our with studies and the the data in The performed X-week on total participants accordance ahead primate dose prior of hold we or our doses requested information hold, dose II CTI-XXXX. due part with data We of of lift Phase an initiating will to quarter. have partial required X the of escalating the receiving FDA FDA a XX-week were XX-milligram having CTI-XXXX been of any highest to In study -- mortality studied. II FDA other the nonclinical the These clinical the with from mortalities submit FDA extensive conclusion the pushed clearance was this be I that imposed in to decision as cohort to a occurred by placebo-controlled submitted to full clinical in exploration to the in we cohort is the placed and analysis trial this dose later the FDA, now CTI-XXXX of nonhuman FA. Phase X hold study. their from were agency the After program now and initiate
program the second as well path gain During as to proposed additional in plan this CTI-XXXX to a on as we dose for cohort II move optimal milligrams in meeting, XX trial, insights Phase forward. development the discuss escalation we the our
meeting, end that work FDA we so as we with balance will extend of XXXX. of expect to cash towards $XXX.X into As of cash million our of half upcoming the runway are we approximately our Thanks quarter. second last the doing the
death Next, data symptoms. FA we landscape of new I'd some autosomal defect be the FA is to caused complications, homozygous on that briefly the produce. are the Ataxia, left only XX% have having the the frataxin on initial by genetic after The and loss a seen symptoms a increase life inability slide.
Symptoms a to critical producing Friedreich’s people. shared FA background patients today. frataxin with With which frataxin is speak GAA myriad XX will with years frataxin. of and XX give heart some she or to repeat clearly FA diagnosis. XX% recessive patient's codon background genetic leads being of with to typical disease some levels context and complications blindness, about from consisting a present patients of the include with on and healthy patient of the to the put XX most producing current debilitating Not X expectancy an start which of are patients repeat, of prevents before the typically in to to The causing rare with a longer devastating side age will treatment the summarized and the around like I'll mitochondrial a enough he less cause protein, GAA XX of of truly disease. of and progressive, of FA to function, symptoms enough common years deafness Unfortunately, in musculoskeletal the often wheelchair-bound diabetes.
advocates indicated and still underlying a of the and therapy FA Because was opinion deficiency and symptoms. there unmet horrible this, While in omaveloxolone this was the need FA's important novel leaders earlier a still approved first increase the to year critically made as breakthrough treat for for it of cause no agents patients, have for is address designed there FA therapies approved to patients what that underlying FA. key clear frataxin pressing are
attention some for start graph frataxin CTI-XXXX. slide. of XX-, levels provide findings This Phase the ascending groups the important your to the design multiple our which left dose summarize Phase program, total Next, changes of informs the normalized and to study from I'd II like clinical sharing I side your briefly proof-of-concept drawing trial. Phase to for of by in in on graph we our key in from XXX-milligram placebo, shows These I'll our for findings baseline the skin protein context today. XX- earlier results provided are and I the dose
because cells tissue in of a makes which collection standardized data subject more a cells, the one less have a method have our variable turnover is and program skin obtained skin rate data tissues turnover clinical collection as than obtained chose available. standardized not and such from We are evaluated from buccal do This as method. skin low relatively types to
for performed cannot study our only XX therefore, be as day XX are and at I Phase trial, Thus, II burdensome in course, we collected in our and they participants. frequently samples and day only XX. trial skin Of skin biopsies baseline baseline, and day Phase at invasive
patients every in XX-milligram then through at days XX the Phase the dosed dosed days. in the third other the levels the for XX-milligram daily should intermittent the this participants dosed ] consecutive skin see were study, then for day were frataxin of in bottom reflect were for I in with measured day results can dosing were day where regime group, day the for XXX-milligram and you As for XX. the the I days. for X to XX dosed daily group the [ dose Phase day at switched in after note I XXX-milligram through X and With daily Participants days the trials XX group group daily slide, of XX. they regimens, mind, exception full that Participants every
dose increase from you results the skin on On and the showed frataxin in represent In groups. baseline at left, the graph graph, and XXX-milligram the dots and compared the from that and the see XXth the a placebo day dose-dependent XXth XX biopsies to in lines a percentile. XX-milligram median horizontal
there frataxin on graph Moving in the can with literature to a cells. you to FA. correlate levels data patients in including body evaluate from on studies buccal buccal neurological see frataxin chose right, the these We buccal is levels cells published cells, cells of with function because indicating
resulting buccal its inherent evaluate concentrations, turnover variability can the types tissue it why data high rate explained the As in in look important before, multiple is these the frataxin noisy, make to and sampling a cell cells of on entirety. which bit data at is and
results median cells together, was and skin from data frataxin consistent, were in you I skin. between pronounced observed buccal though can types in we Phase increase our tissue Taking more see that
we've for data Phase II Importantly, the Phase the with at day daily what final first or us XX-milligram the from in notice XX- that on XX cohort, our cells, and this cohort
Taking trials the as you'll day cohort and capture cohort. for seen XX-milligram a dosing closer for aligns the buccal in section look X X allows to data the I this of XX-milligram XXX-milligram and day
cells the we participants did days remind placebo again milligrams. dosing in for this XXX in increases not compared dose-dependent frataxin Looking only in Though days. Similar cohort. XX see to were at to at skin, from X with in daily increase I'll these clear XX-milligram in buccal you we for dosed a data, that cohort see X frataxin and baseline and daily
XX-milligram Now given cohort, let's next be is FDA that this focus study. aim on the the we will agrees, data to from relevant, the dose which assuming
frataxin data levels take daily away can a day a see is XX, the then increase clear of day and that design II X, X baseline mentioned between Phase we trial. of day earlier, our day look dosing. informs last If key on we the we the I in As which from insight at
day remained in in every II trial. levels our though to included see, it X to a As findings day cell other still day moving above while frataxin, -- baseline. dosing to and regimen led other other can slight These dosing buccal us between day you day XX, an followed to of led explore regimen dosing every initial every that period a dosing by Phase daily decrease
Phase bar our you each On can trial. from where graphs participant slide, this an I next individual represents see
color right the from trial, graph, pharmacodynamic that coding I the the higher believe to from from frataxin to left each the CTI-XXXX. administration. data baseline which for of moving notice concentration provides of at These more proof largest speak and encouraging Looking dosing our dependency with cohorts dose concept you'll increases frequent from in in we came results Phase
This of slide II design trial. Phase our the gears. shows Shifting
with X trial could are randomized participants questions As with Phase was non-ambulatory could XX CTI-XXXX levels enrolls weeks achieved on X dosing with mentioned key raised sustained ambulatory and whether taxing XX earlier, who The by daily dosing, of be and of active informed first frequent are cohort at on dosing. by enrolling with be extended results of with placebo. levels to milligrams X the our FA, and this increased years for following daily weather with I I frataxin CTI-XXXX X:X being, up trial receive participants, least old. or XX less Participants placebo, treatment
further With XX. its this and Participants the to are day days and and of CTI-XXXX, inform design, safety dose long-term through for then first we dose and subcutaneous the PK/PD daily injection regimen. XX the enable day to clinical study aim via characterize continued profiles thereafter other dosed every
Here can similar the demographics demographics posted the our XX, in this on this to enroll the to Phase on Slides website, are and and Since but in our of slides cohort. program. these we'll disease Phase go that X those II see note trial characteristics are you XX-milligram through won't in trials detail participants now, in I I
program. In trial the Phase in in X note addition, II our Phase participated I that previously I'll participants
treated Here are up on and trial which database of data, the key our see of Slide Phase is XX, with our with different from well safety from the with II indicating you II pharmacokinetic been FA XX Overall, our Phase both generally data, With are CTI-XXXX takeaways to tolerated. encouraging. consistent results safety trials each I patients and latest CTI-XXXX. Phase both data that has can
the adverse reactions. severe and common with were The resolved aforementioned single reported reaction that events the adverse site observed dosing Of resolved at to randomized X II mild in least most in placebo. X was Phase randomized drug, trials, who moderate the treated to with withdrawing treatment, cohort, with to X an reactions allergic X a participants. of in no steady site There XX to reaction standard There standard active XX-milligram X discontinued were due participants the event X injection active treatment allergic nor the events enrolled X which was due the Of cohort, X treatment. participants and seen our X participants to of treatment. to placebo injection cohort. adverse injection CTI-XXXX site the which X study medical and reaction were in No events important participants serious with completed
was dosing that in long-term With dose day other cohort last dose and is XX-milligram achieved finding pharmacokinetics, of switched important participants data trial day CTI-XXXX's steady the inform daily to regards regimen. regimen. an to XX, before were the by was This suggest the state will which every day an the dosing from
you supplied cohort protein. change frataxin can administration in results, the frataxin On of skin see data II from XX-milligram concentrations therefore, showing our additional These graph biopsies this total line slide, represent normalized in from baseline CTI-XXXX. with trials, the preliminary top Phase next to the by
XXth the points the medians the while and represent I percentiles Phase left As XXth graph on in the the lines I with the respectively. horizontal results, represent reviewed,
baseline concentrations graph see the X.X treated participants. on median left, picograms day per XX increase protein of CTI placebo-adjusted you microgram from Looking and for frataxin at the on a can
from to how If other period frataxin from data look you day daily XX, when at then switched can the day see every participants during levels the dosing. you changed
Looking decreased can between these baseline you levels remains see skin though that in the frataxin above time points, levels. median
results daily together we increase us suggest provide Taken first, at skin dosing XX they skin with learnings; with XX important with X frataxin day milligrams. data, in can only of these CTI-XXXX
symptoms, Given a frataxin speaks provide we deficiency CTI-XXXX's is to a crucial benefit. finding is devastating what clinical this to that potential FA's underlies believe
Second, suggest we both preliminary a daily They, at regimen maintain a Phase key that group. when dosing XX may be preferred trial, XX-milligram these going in to to the dosing into questions provide increases results frataxin of answer milligrams, levels. therefore, our II had
this from cohorts and will data Additional future studies understanding. enhance
graph Moving on right. on the at the to look
day You from for at of the on bar an with day X an quantifiable available, XX. treated shown had these or quantitative quantification can levels sample limit reaction. data not Of a data participant there they more one detailed of there also changes in Each receiving XX below increase was baseline. allergic I'll CTI-XXXX that either from participant due who tests because And with to from study one and of no all CTI-XXXX levels XX, participants baseline with frataxin achieved X representation who day participants was concentrations at skin see baseline frataxin but the in day the frataxin representations. while in had of point on excluded individual frataxin XX increased skin no an had out represents participant placebo levels participants the at levels. discontinued
in frataxin on Here XX, see as data from data cells, buccal concentration with Slide again, can you baseline. changes shown from the
variability cells was used cells at rapid saw should in I consistent day buccal baseline sampling the concentration inherent of to are median from and the turnover. in the we these per increase to noisy that note, placebo-adjusted As data what a of their however, bit collect technique with due likely skin. there picograms X.X in protein see, XX, microgram you can a frataxin
see day day Turning to days that XX the graph, we section frataxin next can the our CTI-XXXX. after back to approximately of on attention decreased XX administration levels baseline of of alternate
at buccal day on concentrations of from placebo data X participants, patients. also quantitative with both I'll participants have data to cell on baseline X participants do of XX Looking of neither increased day quantifiable has the XX note that at baseline X available and X levels out frataxin day at on frataxin individual XX. not CTI-XXXX placebo either or compared
very from to Taking pleased our the sets, Phase when observation throughout aiming in our we as and results daily increases maintain of together, skin preference frataxin. that the as the show increases are I Phase data in consistency for trials buccal cells administration from and both data frataxin II the well
Given deficiency the FA's we as in central role, an encouraging view this pathophysiology, frataxin plays finding.
provide quarter plan CTI-XXXX meeting. after the upcoming update chance look we our we to in next we ahead, regulatory FDA the As have feedback third had from on to get our
cohort XX-milligram Our to the Phase utilized would a same clearance move which trial cohort. in schedule II evaluate goal to XX-milligram FDA to gain in dosing the is the
safety, currently Looking assuming and as plan we clinical also frataxin regimen our is trial will dose FA be double-blind to placebo-controlled a in are II and a study are valuable multiple between who clearance FA perspective drugs pediatric dose, levels bit of to old. provide road, trials ability further I, proceed, and current information receive XX inform potentially from FDA includes impact of ascending turn are there clinical function. XX.
Collectively, extension who under and to for expected development This years CTI-XXXX open-label to pivotal our effective and in exciting dose this a believe open-label trial. are approved trial clinical down a the We information with global the individuals results related X Phase with individuals to pediatric expected in design no increase for particularly Phase extension our CTI-XXXX the
Ataxia. summarize believe underlying presentation, point intended deficiency and first in are We development protein To address the increase at exciting frataxin our CTI-XXXX's levels we today's CTI-XXXX's to days. Phase therapeutic important when dosed as I as -- Friedreich’s do milligrams was least and and the for first at in data this increases demonstrated X we potential to tissues XX at saw peripheral frataxin CTI-XXXX for daily an
built We and increase II daily can demonstrate on data XX for skin buccal Phase of in cells have with results days. frataxin now these we dosing XX with milligrams that proof-of-concept
the a with are We to to initiate preparing latest of subsequent our gaining with II discuss a cohort. the goal a FDA cohort dose our to of evaluating to identical now results regimen first clearance Phase XX-milligram meet with that
expect be in next the update our We quarter. will third
Ataxia Finally, for the of Addressing thank investigators I to Research their to of development. key its remains in we commend exciting for whom open also helped bravery participants dedication. to trial call unmet I of with all regulatory before FDA Friedreich’s questions, throughout advocates would I far their the the all thank this and engagement families. thus the CTI-XXXX Larimar clinical point inspiration, our individuals and their would needs at the FA partners, Alliance, employees, and as get patient like process our like source as well the talented and
With open for the line that, Operator? questions. we now will
